In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.
Example: SECTION 1. LIABILITY OF BUSINESS ENTITIES PROVIDING USE OF FACILITIES
TO NONPROFIT ORGANIZATIONS.

(a) Definitions.--In this section:
(1) Business entity.--The term ''business entity'' means a
firm, corporation, association, partnership, consortium, joint
venture, or other form of enterprise.
(2) Facility.--The term ''facility'' means any real
property, including any building, improvement, or appurtenance.
(3) Gross negligence.--The term ''gross negligence'' means
voluntary and conscious conduct by a person with knowledge (at
the time of the conduct) that the conduct is likely to be
harmful to the health or well-being of another person.
(4) Intentional misconduct.--The term ''intentional
misconduct'' means conduct by a person with knowledge (at the
time of the conduct) that the conduct is harmful to the health
or well-being of another person.
(5) Nonprofit organization.--The term ''nonprofit
organization'' means--
(A) any organization described in section 501(c)(3)
of the Internal Revenue Code of 1986 and exempt from
tax under section 501(a) of such Code; or
(B) any not-for-profit organization organized and
conducted for public benefit and operated primarily for
charitable, civic, educational, religious, welfare, or
health purposes.
(6) State.--The term ''State'' means each of the several
States, the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, Guam, American Samoa, the Northern
Mariana Islands, any other territory or possession of the
United States, or any political subdivision of any such State,
territory, or possession.
(b) Limitation on Liability.--
(1) In general.--Subject to subsection (c), a business
entity shall not be subject to civil liability relating to any
injury or death occurring at a facility of the business entity
in connection with a use of such facility by a nonprofit
organization if--
(A) the use occurs outside of the scope of business
of the business entity;
(B) such injury or death occurs during a period
that such facility is used by the nonprofit
organization; and
(C) the business entity authorized the use of such
facility by the nonprofit organization.
(2) Application.--This subsection shall apply--
(A) with respect to civil liability under Federal
and State law; and
(B) regardless of whether a nonprofit organization
pays for the use of a facility.
(c) Exception for Liability.--Subsection (b) shall not apply to an
injury or death that results from an act or omission of a business
entity that constitutes gross negligence or intentional misconduct,
including any misconduct that--
(1) constitutes a crime of violence (as that term is
defined in section 16 of title 18, United States Code) or act
of international terrorism (as that term is defined in section
2331 of title 18) for which the defendant has been convicted in
any court;
(2) constitutes a hate crime (as that term is used in the
Hate Crime Statistics Act (28 U.S.C. 534 note));
(3) involves a sexual offense, as defined by applicable
State law, for which the defendant has been convicted in any
court; or
(4) involves misconduct for which the defendant has been
found to have violated a Federal or State civil rights law.
(d) Superseding Provision.--
(1) In general.--Subject to paragraph (2) and subsection
(e), this Act preempts the laws of any State to the extent that
such laws are inconsistent with this Act, except that this Act
shall not preempt any State law that provides additional
protection from liability for a business entity for an injury
or death with respect to which conditions under subparagraphs
(A) through (C) of subsection (b)(1) apply.
(2) Limitation.--Nothing in this Act shall be construed to
supersede any Federal or State health or safety law.
(e) Election of State Regarding Nonapplicability.--This Act shall
not apply to any civil action in a State court against a business
entity in which all parties are citizens of the State if such State
enacts a statute--
(1) citing the authority of this subsection;
(2) declaring the election of such State that this Act
shall not apply to such civil action in the State; and
(3) containing no other provision.
Example solution: Shields a business entity from civil liability relating to any injury or death occurring at a facility of that entity in connection with a use of such facility by a nonprofit organization if: (1) the use occurs outside the scope of business of the business entity; (2) such injury or death occurs during a period that such facility is used by such organization; and (3) the business entity authorized the use of such facility by the organization.
Makes this Act inapplicable to an injury or death that results from an act or omission of a business entity that constitutes gross negligence or intentional misconduct, including misconduct that: (1) constitutes a hate crime or a crime of violence or act of international terrorism for which the defendant has been convicted in any court; or (2) involves a sexual offense for which the defendant has been convicted in any court or misconduct for which the defendant has been found to have violated a Federal or State civil rights law.
Preempts State laws to the extent that such laws are inconsistent with this Act, except State law that provides additional protection from liability. Specifies that this Act shall not be construed to supersede any Federal or State health or safety law.
Makes this Act inapplicable to any civil action in a State court against a business entity in which all parties are citizens of the State if such State, citing this Act's authority and containing no other provision, enacts a statute declaring the State's election that this Act shall not apply to such action in the State.
Example explanation: This Bill focuses on shielding business entities from civil liability relating to an injury or death depending on the conditions of injury, hence the generated summary is correct.

Problem: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Microbicide Development Act of
2001''.

SEC. 2. FINDINGS.

The Congress finds as follows:
(1) Sexually transmitted diseases (''STDs'') and the human
immunodeficiency virus (''HIV'') are producing serious and
costly epidemics of infectious disease in populations
worldwide.
(2) This year, 15,400,000 people in the United States will
acquire a new STD.
(3) Globally, 36,100,000 people are infected with HIV, with
more than 15,000 new infections occurring daily.
(4) Racial and ethnic minorities have been
disproportionately infected with STDs, especially HIV. For
example, although together African American and Latina women
represent roughly 25 percent of the total U.S. female
population, they account for 77 percent of all reported female
HIV cases.
(5) STDs cause serious, costly, even deadly conditions for
women and their children: infertility, pregnancy complications,
cervical cancer, infant mortality, and higher risk of
contracting HIV.
(6) Estimated annual costs of STDs and their complications
in the United States range from $8,400,000,000 in direct
medical costs to nearly $20,000,000,000, including out-of-
pocket costs and lost productivity.
(7) Microbicides are a promising new technology for STD and
HIV prevention.
(8) Microbicides are user-controlled products that could
kill or inactivate the bacteria and viruses that cause STDs and
HIV.
(9) Microbicides would fill a critical gap in the array of
STD-prevention technologies, first as an important backup or
alternative to the condom, and second, as a technology that,
unlike most vaccines, could offer protection against various
STDs, not just HIV.
(10) Several potential microbicides are poised for
successful development; more than 20 products are in clinical
trials and nearly 35 promising compounds exist that could be
investigated further.
(11) Studies into the market potential for microbicides
indicate that they would have broad appeal. One nationally
representative survey indicated that at least 21,000,000
sexually active women in the United States would be interested
in such products, if they were available.
(12) Federal support for microbicide research and
development is crucial.
(13) At present, there appear to be insufficient perceived
economic incentives for pharmaceutical companies to become
actively engaged in microbicide research and development.
(14) Numerous small biotechnology companies and university
researchers are actively engaged in microbicide research, but
they are almost totally dependent on public-sector grants to
continue their work and test their products.
(15) Despite public health need and tremendous scientific
opportunity, microbicide research and development currently
receives less than 1 percent of the Federal HIV research
budget--not nearly enough to keep pace with the raging STD and
HIV epidemics.
(16) Existing public sector grants for microbicides are too
small and too short-term to move product leads forward, and the
availability of clinical trial sites is limited by funding
constraints.
(17) There is a backlog in the research and development
pipeline, so that innovative and promising product concepts are
languishing, while infection rates are growing.
(18) For significant progress to be made, the current
amount of Federal investment needs to increase to $75,000,000
in fiscal year 2002, to $100,000,000 in fiscal year 2003, with
$100,000,000 yearly in the successive out-years as required, in
order to sustain multiyear funding at a productive level.

TITLE I--MICROBICIDE RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH

SEC. 101. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES;
PROGRAM REGARDING MICROBICIDES FOR PREVENTING
TRANSMISSION OF HIV AND OTHER SEXUALLY TRANSMITTED
DISEASES.

Subpart 6 of part C of title IV of the Public Health Service Act
(42 U.S.C. 285f et seq.) is amended by adding at the end the following
section:

''microbicides for preventing transmission of hiv and other sexually
transmitted diseases

''Sec. 447C. (a) Expansion and Coordination of Activities.--The
Director of the Institute shall expand, intensify, and coordinate the
activities of the Institute with respect to research on the development
of microbicides to prevent the transmission of HIV and other sexually
transmitted diseases (in this section referred to as 'microbicide
research').
''(b) Coordination With Other Institutes.--The Director of the
Institute shall coordinate the activities under subsection (a) among
all appropriate institutes and components of the National Institutes of
Health to the extent such institutes and components have
responsibilities that are related to the development of microbicides.
''(c) Research Plan.--
''(1) In general.--The Director of the Institute, acting in
consultation with the Director of the Office of AIDS Research,
shall develop a comprehensive research plan for the conduct and
support of research and development of microbicides (in this
section referred to as the 'Research Plan'), and shall annually
review and as appropriate revise the plan.
''(2) Requirements.--The Research Plan shall--
''(A) identify current microbicide research and
development activities conducted or supported by the
National Institutes of Health, including a description
of each current grant and contract mechanism explicitly
designed to facilitate microbicide research, including
support for preclinical product development and
clinical trial capacity; and
''(B) describe microbicide research and development
opportunities for the five year period beginning six
months after the date of the enactment of the
Microbicide Development Act of 2001, including
professional judgment funding projections, description
of objectives with respect to microbicide research,
description of the institutes involved and their role
in microbicide research, plans for enhancing the
capacity of such institutes to carry out the research
opportunities, including staffing and resources
necessary for carrying out the activities of this
section, and discussion of plans for increasing number
of investigators in this area of research.
''(3) Consultation.--In developing the Research Plan, the
Director of the Institute shall work in close consultation with
all appropriate institutes and components at the National
Institutes for Health that have responsibilities that are
related to the development of microbicides, with the
microbicide research community, and with health advocates.
''(4) Submission of initial plan to president and
congress.--
''(A) In general.--The initial Research Plan shall
be developed not later than six months after the date
of the enactment of the Microbicide Development Act of
2001. The Director of the Institute shall transmit such
Plan to the Director of NIH, who shall submit the Plan
to the President and the Congress.
''(B) Relation to requirement of biennial nih
report.--Subparagraph (A) shall be carried out
independently of the process of reporting that is
required in section 403.
''(d) Program for Microbicide Development.--
''(1) In general.--In carrying out subsection (a), the
Director of the Institute shall establish a program to support
research to develop microbicides that can substantially reduce
transmission of HIV and other sexually transmitted diseases.
Activities under such program shall provide for an expansion
and intensification of the conduct and support of--
''(A) basic research on the initial mechanisms of
infection by sexually transmitted pathogens;
''(B) development of appropriate animal models for
evaluating safety and efficacy of microbicides;
''(C) development of formulation and delivery
approaches;
''(D) research on targeted designs of microbicides;
''(E) manufacture of candidate products for testing
in animals and humans;
''(F) conduct of HIV incidence and microbicide
feasibility studies;
''(G) evaluation of microbicides in clinical
trials, both domestically and internationally; and
''(H) behavioral research on use, acceptability,
and adherence to microbicides.
''(2) Research branch.--The Director of the Institute shall
establish, within the Vaccine and Prevention Research Program
of the Division of AIDS in the Institute, an organizational
unit to be known as the Microbicide Research Branch. Such
Branch shall carry out the program under this subsection.
''(e) Construction of Facilities.--The Director of the Institute
may make awards of grants and contracts to public and nonprofit private
entities for the construction of facilities to conduct microbicide
research, including clinical trials.
''(f) Centers for Microbicide Research and Development.--
''(1) In general.--The Director of the Institute, after
consultation with the advisory council for the Institute, and
in consultation with the Director of the Office of AIDS
Research, shall make awards of grants or contracts to public
and nonprofit private entities for the development and
operation of not less than four multidisciplinary research
centers to conduct microbicide research.
''(2) Requirements.--Each center assisted under this
subsection shall--
''(A) use the facilities of a single institution,
or be formed from a consortium of cooperating
institutions, meeting such requirements as may be
prescribed by the Director of the Institute; and
''(B) conduct basic research on muscosal
transmission to design novel microbicide strategies for
the prevention of HIV and STD infection, including
research into HIV and STD pathogenesis, reproductive
tract biology and toxicology, concept testing in animal
models, and formulation and delivery design.
''(g) Report to Congress.--Not later than one year after the date
of the initial submission of the Research Plan under subsection (c)(1),
and annually thereafter, the Director of the Institute shall submit to
the Committee on Energy and Commerce in the House of Representatives
and the Committee on Health, Education, Labor and Pensions in the
Senate a report that describes the activities of the Institute
regarding microbicide research. Each such report shall include--
''(1) an updated Research Plan, including professional
judgment funding projections;
''(2) an assessment of the implementation of such plan;
''(3) a description and evaluation of the progress made,
during the period for which such report is prepared, in the
research on microbicides;
''(4) a summary and analysis of expenditures made, during
the period for which the report is made, for activities with
respect to microbicides research conducted and supported by the
National Institutes of Health, including the number of full-
time equivalent employees; and
''(5) such comments and recommendations as the Director of
the Institute considers appropriate.
''(h) Coordination With Other Federal Agencies.--The Director of
the Institute shall consult with the Director for the Centers for
Disease Control and Prevention and the United States Agency for
International Development in developing the Research Plan that takes
into consideration research on HIV and other sexually transmitted
diseases and microbicides carried out at the Centers for Disease
Control and Prevention and the United States Agency for International
Development.
''(i) Definition.--For purposes of this section, the term 'HIV'
means the human immunodeficiency virus. Such term includes acquired
immune deficiency syndrome.
''(j) Authorization of Appropriations.--For the purposes of
carrying out this section, there are authorized to be appropriated such
sums as may be necessary for each of the fiscal years 2002 through
2004.''.

TITLE II--MICROBICIDE RESEARCH AT THE CENTERS FOR DISEASE CONTROL AND
PREVENTION

SEC. 201. MICROBICIDES FOR PREVENTING TRANSMISSION OF HIV AND OTHER
SEXUALLY TRANSMITTED DISEASES.

Part B of title III of the Public Health Service Act (42 U.S.C. 243
et seq.) is amended by inserting after section 317P the following
section:

''microbicides for preventing transmission of hiv and other sexually
transmitted diseases

''Sec. 317Q. (a) Expansion and Coordination of Microbicide Research
Activities.--The Secretary, acting through the Director of the Centers
for Disease Control and Prevention, shall expand, intensify, and
coordinate the activities of such Centers with respect to research on
microbicides to prevent the transmission of HIV and other sexually
transmitted diseases.
''(b) Grants Regarding Microbicide Research.--In order to
contribute to the rapid evaluation of safe and effective microbicides
for the prevention of HIV and other sexually transmitted diseases, the
Secretary may in carrying out subsection (a) make grants to public and
nonprofit private entities for the purpose of--
''(1) laboratory research in preparation for, and support
of, clinical microbicide trials;
''(2) conducting behavioral research in preparation for,
and support of, clinical microbicide trials;
''(3) developing and characterizing domestic populations
and international cohorts appropriate for Phase I, II, and III
clinical trials of candidate topical microbicides;
''(4) conducting Phase I and II clinical trials to assess
the safety and acceptability of candidate microbicides;
''(5) conducting Phase III clinical trials to assess the
efficacy of candidate microbicides;
''(6) provide technical assistance to, and consultation
with, a wide variety of domestic and international entities
involved in developing and evaluating topical microbicides,
including health agencies, extramural researchers, industry,
health advocates, and non-profit organizations; and
''(7) developing and evaluating the diffusion and effects
of implementation strategies for use of effective topical
microbicides.
''(c) Selection of Agents and Trial Designs; Coordination With
Other Agencies.--In coordination and collaboration with the Director of
the National Institutes of Health and the Administrator of the United
States Agency for International Development, the Secretary shall select
agents and trial designs, develop clinical trial capacity as described
in subsection (b), share experience, and avoid duplication of effort.
''(d) Annual Reports.--Not later than six months after the date of
the enactment of the Microbicide Development Act of 2001, and annually
thereafter, the Secretary shall submit to the Energy and Commerce
Committee in the House of Representatives and the Health, Education,
Labor and Pensions Committee in the Senate a report on the activities
carried out under this section by the Secretary. Each such report shall
include--
''(1) description of research with respect to microbicide
research and development;
''(2) description and evaluation of the progress made,
during the period for which such report is prepared, in the
research on microbicides; and
''(3) summary and analysis of expenditures made, during the
period for which the report is made, for activities with
respect to microbicides conducted and supported by the Centers
for Disease Control and Prevention.
''(e) Definition.--For the purposes of this section, the term 'HIV'
means the human immunodeficiency virus. Such term includes acquired
immune deficiency syndrome.
''(f) Authorization of Appropriations.--For the purposes of
carrying out this section, there are authorized to be appropriated such
sums as may be necessary for each of the fiscal years 2002 through
2004.''.
Solution: Microbicide Development Act of 2001 - Amends the Public Health Service Act to direct the Director of the National Institute of Allergy and Infectious Diseases to expand, intensify, and coordinate the activities of the Institute with respect to research on the development of microbicides to prevent the transmission of HIV and other sexually transmitted diseases.Directs the Secretary of Health and Human Services to expand, intensify, and coordinate the activities of such Centers with respect to research on microbicides to prevent the transmission of HIV and other sexually transmitted diseases.